Abbott Splits Into Two

Abbott announced that it will separate into two publicly traded companies, one its $18-billion pharma unit and the other its $22-billion diversified medical products business. The research-based pharmaceutical company, which has yet to be named, will be led by 30-year Abbott veteran Richard Gonzalez, currently EVP for global pharmaceuticals. It will focus on “select specialty products” Abbott said.

Read the article in MM&M